Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017

FDA: No Harm in MRI Gadolinium Retention in the Brain

Gadolinium-based Contrast Agents for Magnetic Resonance Imaging (MRI): Drug Safety Communication - No Harmful Effects Identified With Brain Retention

FDA says gadolinium retention in the brain is not a safety issue

May 25, 2017 — A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for magnetic resonance imaging (MRI) has not identified adverse health affects from gadolinium retained in the brain. The FDA released a drug safety communication regarding all gadolinium-based contrast agents (GBCAs) earlier this week. 

The FDA said GBCAs may be associated with some gadolinium retention in the brain and other body tissues. However, the FDA said there is no evidence to date that gadolinium retention in the brain from any of the GBCAs is harmful. The agency said this includes GBCAs associated with higher retention of gadolinium. These findings prompted the FDA say restricting GBCA use is not warranted at this time. FDA said it will continue to assess the safety of GBCAs and plan to have a public meeting to discuss this issue in the future.

The agency said it evaluated scientific publications and adverse event reports submitted to FDA. Some human and animal studies looked at GBCA use over periods longer than a year. These publications and reports show that gadolinium is retained in organs such as the brain, bones and skin. The publications show that linear GBCAs retain more gadolinium in the brain than macrocyclic GBCAs. However, the review did not identify adverse health effects related to this brain retention.

The FDA continues to assess the safety of GBCAs. FDA’s National Center for Toxicological Research is conducting a study on brain retention of GBCAs in rats. Other research is also being conducted about how gadolinium is retained in the body. FDA will update the public when new information becomes available, and a public meeting to discuss results will be held in the future.

The intravenous gadolinium contrast media specifically mentioned in the safety communication includes:
• Ablavar (gadofosveset trisodium) 
• Dotarem (gadoterate meglumine) 
• Eovist (gadoxetate disodium) 
• Gadavist (gadobutrol) 
• Magnevist (gadopentetate dimeglumine) 
• MultiHance (gadobenate dimeglumine) 
• Omniscan (gadodiamide) 
• OptiMARK (gadoversetamide) 
• ProHance (gadoteridol)

The FDA recommendations for healthcare professionals and patients remains unchanged from July 2015, when FDA first informed the public that it was investigating this potential risk with GBCAs. 

The agency said the agents should be used as is appropriate when considering the use of any medical imaging agent. It also stated healthcare professionals should limit GBCA use to circumstances in which additional information provided by the contrast agent is necessary and to assess the necessity of repetitive MRIs with GBCAs. 

The FDA said retention of gadolinium affects only GBCAs and does not apply to other types of scanning agents used for other imaging procedures, including iodine-based contrast used in X-ray and computed tomography (CT) imaging or radioisotopes used in PET or SPECT nuclear imaging.

For more information, watch the VIDEO “MRI Gadolinium Contrast Retention in the Brain.” This is an interview with Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pittsburgh Medical Center, at RSNA 2016. He was involved in the key studies regarding gadolinium retention in the brain.

Read the article Gadolinium May Remain in Brain After Contrast MRI

Read the article MRIs During Pregnancy Are Safe, But Gadolinium Scans May Increase Risk to Fetus

 

For more information: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm559709.htm

 

Related Content

 Many patients with severe coronavirus disease 2019 (COVID-19) remain unresponsive after surviving critical illness. Investigators led by a team at Massachusetts General Hospital (MGH) now describe a patient with severe COVID-19 who, despite prolonged unresponsiveness and structural brain abnormalities, demonstrated functionally intact brain connections and weeks later he recovered the ability to follow commands

Getty Images

News | Coronavirus (COVID-19) | July 08, 2020
July 8, 2020 — Many patients with severe coronavirus disease 2019 (...
A patient implanted with the Axonics System can undergo MRI examinations safely with radio frequency (RF) Transmit Body or Head Coil under the conditions outlined in the Axonics MRI Conditional Guidelines.

A patient implanted with the Axonics System can undergo MRI examinations safely with radio frequency (RF) Transmit Body or Head Coil under the conditions outlined in the Axonics MRI Conditional Guidelines.

News | Magnetic Resonance Imaging (MRI) | July 02, 2020
July 2, 2020 — Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commerci
This data represents wave 2 of a QuickPoLL survey conducted in partnership with an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business

Getty Images

Feature | Coronavirus (COVID-19) | July 01, 2020 | By Melinda Taschetta-Millane
Researchers reviewed results of prostate biopsies on over 3,400 men who had targets identified on prostate MRI and found that the positive predictive value of the test for prostate cancer was highly variable at different sites
News | Prostate Cancer | July 01, 2020
July 1, 2020 — Prostate MRI is an emerging technology used to identify and guide treatment for...
R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

News | Magnetic Resonance Imaging (MRI) | July 01, 2020
July 1, 2020 — Researchers using magnetic...
In new QuickPoLL survey on imaging during the pandemic, responses were tallied from around 170 radiology administrators and business managers, who are part of an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business. TMTG is a research firm specializing in the medical device, healthcare and pharmaceutical industries.
Feature | Coronavirus (COVID-19) | June 30, 2020 | By Melinda Taschetta-Millane
Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

News | Pediatric Imaging | June 29, 2020
June 29, 2020 — A type of smart magnetic r...
This image of DCE-MRI reveals persistent blood brain barrier disorder in American football players. Using brain imaging techniques and analytical methods, researchers can determine whether football players have CTE by measuring leakage of the blood-brain barrier. Image courtesy of Ben-Gurion University

This image of DCE-MRI reveals persistent blood brain barrier disorder in American football players. Using brain imaging techniques and analytical methods, researchers can determine whether football players have CTE by measuring leakage of the blood-brain barrier. Image courtesy of Ben-Gurion University

News | Magnetic Resonance Imaging (MRI) | June 22, 2020
June 22, 2020 — Chronic traumatic encephalopathy (CTE), a neurodegenerative disease caused by repeated...